We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00023166
Recruitment Status : Terminated
First Posted : August 27, 2001
Last Update Posted : June 24, 2005
Information provided by:
Enzon Pharmaceuticals, Inc.

Brief Summary:
Studies of PEG-paclitaxel have been terminated

Condition or disease Intervention/treatment Phase
Neoplasm Lymphomas Neoplasm Metastasis Drug: PEG-paclitaxel Phase 1

Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors and Lymphomas
Study Start Date : May 2001
Estimated Study Completion Date : May 2002

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
Drug Information available for: Paclitaxel
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
None - Study has been terminated.

ClinicalTrials.gov Identifier: NCT00023166     History of Changes
Other Study ID Numbers: PTX-5001
First Posted: August 27, 2001    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: March 2004

Keywords provided by Enzon Pharmaceuticals, Inc.:
Phase I
Open label
Advanced primary and/or metastatic solid tumors
Neoplasm metastasis

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplastic Processes
Pathologic Processes
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action